Starpharma Holdings Stock Performance
| SPHRY Stock | USD 3.55 0.75 26.79% |
On a scale of 0 to 100, Starpharma Holdings holds a performance score of 9. The entity has a beta of -1.14, which indicates a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Starpharma Holdings are expected to decrease slowly. On the other hand, during market turmoil, Starpharma Holdings is expected to outperform it slightly. Please check Starpharma Holdings' total risk alpha, as well as the relationship between the downside variance and rate of daily change , to make a quick decision on whether Starpharma Holdings' existing price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Starpharma Holdings are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile basic indicators, Starpharma Holdings showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 60.5 M | |
| Total Cashflows From Investing Activities | -836 K |
Starpharma |
Starpharma Holdings Relative Risk vs. Return Landscape
If you would invest 260.00 in Starpharma Holdings on November 16, 2025 and sell it today you would earn a total of 95.00 from holding Starpharma Holdings or generate 36.54% return on investment over 90 days. Starpharma Holdings is currently producing 0.652% returns and takes up 5.5569% volatility of returns over 90 trading days. Put another way, 49% of traded otc stocks are less volatile than Starpharma, and 87% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Starpharma Holdings Target Price Odds to finish over Current Price
The tendency of Starpharma OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.55 | 90 days | 3.55 | near 1 |
Based on a normal probability distribution, the odds of Starpharma Holdings to move above the current price in 90 days from now is near 1 (This Starpharma Holdings probability density function shows the probability of Starpharma OTC Stock to fall within a particular range of prices over 90 days) .
Starpharma Holdings Price Density |
| Price |
Predictive Modules for Starpharma Holdings
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Starpharma Holdings. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Starpharma Holdings Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Starpharma Holdings is not an exception. The market had few large corrections towards the Starpharma Holdings' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Starpharma Holdings, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Starpharma Holdings within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.88 | |
β | Beta against Dow Jones | -1.14 | |
σ | Overall volatility | 0.25 | |
Ir | Information ratio | 0.13 |
Starpharma Holdings Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Starpharma Holdings for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Starpharma Holdings can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Starpharma Holdings is way too risky over 90 days horizon | |
| Starpharma Holdings appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 4.68 M. Net Loss for the year was (16.15 M) with loss before overhead, payroll, taxes, and interest of (9.29 M). | |
| Starpharma Holdings has accumulated about 49.92 M in cash with (13.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22. |
Starpharma Holdings Fundamentals Growth
Starpharma OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Starpharma Holdings, and Starpharma Holdings fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Starpharma OTC Stock performance.
| Return On Equity | -0.29 | |||
| Return On Asset | -0.14 | |||
| Operating Margin | (3.13) % | |||
| Current Valuation | 123.62 M | |||
| Shares Outstanding | 40.89 M | |||
| Price To Earning | 43.64 X | |||
| Price To Book | 4.88 X | |||
| Price To Sales | 26.73 X | |||
| Revenue | 4.68 M | |||
| EBITDA | (16.63 M) | |||
| Cash And Equivalents | 49.92 M | |||
| Cash Per Share | 1.22 X | |||
| Total Debt | 4 M | |||
| Debt To Equity | 0.17 % | |||
| Book Value Per Share | 1.18 X | |||
| Cash Flow From Operations | (13.16 M) | |||
| Earnings Per Share | (0.31) X | |||
| Total Asset | 66.17 M | |||
| Retained Earnings | (114.58 M) | |||
| Current Asset | 37.44 M | |||
| Current Liabilities | 7.13 M | |||
About Starpharma Holdings Performance
Evaluating Starpharma Holdings' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Starpharma Holdings has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Starpharma Holdings has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company was founded in 1996 and is headquartered in Abbotsford, Australia. Starpharma Hlds operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 50 people.Things to note about Starpharma Holdings performance evaluation
Checking the ongoing alerts about Starpharma Holdings for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Starpharma Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Starpharma Holdings is way too risky over 90 days horizon | |
| Starpharma Holdings appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 4.68 M. Net Loss for the year was (16.15 M) with loss before overhead, payroll, taxes, and interest of (9.29 M). | |
| Starpharma Holdings has accumulated about 49.92 M in cash with (13.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22. |
- Analyzing Starpharma Holdings' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Starpharma Holdings' stock is overvalued or undervalued compared to its peers.
- Examining Starpharma Holdings' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Starpharma Holdings' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Starpharma Holdings' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Starpharma Holdings' otc stock. These opinions can provide insight into Starpharma Holdings' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Starpharma OTC Stock Analysis
When running Starpharma Holdings' price analysis, check to measure Starpharma Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Starpharma Holdings is operating at the current time. Most of Starpharma Holdings' value examination focuses on studying past and present price action to predict the probability of Starpharma Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Starpharma Holdings' price. Additionally, you may evaluate how the addition of Starpharma Holdings to your portfolios can decrease your overall portfolio volatility.